First Turn Management LLC Makes New Investment in ADMA Biologics, Inc. (NASDAQ:ADMA)

First Turn Management LLC bought a new stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 664,985 shares of the biotechnology company's stock, valued at approximately $13,293,000. ADMA Biologics makes up approximately 2.1% of First Turn Management LLC's holdings, making the stock its 27th largest holding. First Turn Management LLC owned approximately 0.29% of ADMA Biologics at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of ADMA. Hollencrest Capital Management purchased a new position in ADMA Biologics in the 3rd quarter valued at approximately $30,000. Quest Partners LLC purchased a new position in shares of ADMA Biologics in the second quarter valued at $29,000. EntryPoint Capital LLC acquired a new position in shares of ADMA Biologics during the 1st quarter worth $31,000. USA Financial Formulas boosted its position in shares of ADMA Biologics by 8.6% in the 3rd quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company's stock worth $136,000 after buying an additional 539 shares in the last quarter. Finally, CWM LLC grew its stake in ADMA Biologics by 114.2% in the 2nd quarter. CWM LLC now owns 8,192 shares of the biotechnology company's stock valued at $92,000 after acquiring an additional 4,367 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Trading Up 5.6 %

Shares of ADMA traded up $1.09 on Tuesday, hitting $20.63. 2,200,298 shares of the stock traded hands, compared to its average volume of 3,656,222. ADMA Biologics, Inc. has a 1 year low of $3.60 and a 1 year high of $23.64. The stock's 50 day moving average is $18.57 and its two-hundred day moving average is $14.54. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $4.88 billion, a P/E ratio of 71.25 and a beta of 0.64.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.13 by $0.02. The business had revenue of $119.84 million for the quarter, compared to analyst estimates of $107.25 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. During the same period in the prior year, the firm posted $0.01 EPS. As a group, sell-side analysts predict that ADMA Biologics, Inc. will post 0.52 earnings per share for the current year.

Insider Transactions at ADMA Biologics

In other ADMA Biologics news, Director Lawrence P. Guiheen sold 9,000 shares of the company's stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $18.47, for a total value of $166,230.00. Following the completion of the transaction, the director now directly owns 153,941 shares of the company's stock, valued at $2,843,290.27. This represents a 5.52 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Adam S. Grossman sold 236,889 shares of ADMA Biologics stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $17.69, for a total value of $4,190,566.41. Following the sale, the chief executive officer now directly owns 2,059,726 shares in the company, valued at approximately $36,436,552.94. The trade was a 10.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 466,900 shares of company stock valued at $8,224,121 over the last quarter. Company insiders own 3.70% of the company's stock.

Wall Street Analysts Forecast Growth

ADMA has been the subject of a number of research reports. HC Wainwright lifted their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a "buy" rating in a research report on Friday, November 8th. Raymond James lifted their price objective on ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a research report on Friday, November 8th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $20.00 target price on shares of ADMA Biologics in a report on Friday, September 20th.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.